Latest Global Health News

Page 3 of 7
Patrys Limited has completed its acquisition of Reliis Pty Ltd, adding a promising injectable quetiapine program to its clinical pipeline and strengthening its board with two new directors.
Ada Torres
Ada Torres
28 Jan 2026
Atomo Diagnostics has locked in exclusive global rights to a novel liver function test that rapidly detects liver injury, expanding its footprint in point-of-care diagnostics. The test, delivered on Atomo’s Pascal platform, targets drug-induced liver injury and chronic liver conditions with significant commercial potential.
Ada Torres
Ada Torres
20 Jan 2026
Global Health Limited reports a robust 23% increase in customer receipts and an 85% jump in quarterly operating cashflow, as it advances its transition to AI-enabled SaaS platforms targeting profitability by June 2026.
Ada Torres
Ada Torres
19 Jan 2026
Proteomics International has been granted a Canadian patent for its PromarkerEso blood test, a pioneering diagnostic tool for early detection of esophageal adenocarcinoma. This milestone strengthens its global intellectual property portfolio and paves the way for commercial expansion in North America.
Ada Torres
Ada Torres
16 Jan 2026
Atomo Diagnostics has landed a significant $502,000 order for HIV self-tests destined for an African country, underscoring sustained demand for accessible diagnostics in the region.
Ada Torres
Ada Torres
15 Jan 2026
Recce Pharmaceuticals has received a $5.3 million R&D tax rebate from the Australian Taxation Office, providing a significant cash injection to support its innovative synthetic anti-infective drug development programs.
Ada Torres
Ada Torres
14 Jan 2026
Anatara Lifesciences reports encouraging pre-clinical results for its anti-obesity candidate AOC, demonstrating significant reductions in weight regain and visceral fat in mice. However, a delay in mechanism of action studies pushes full data release to January 2026.
Ada Torres
Ada Torres
17 Dec 2025
Recce Pharmaceuticals has won a significant Australian Government R&D tax incentive, unlocking up to A$85 million for its synthetic anti-infective programs worldwide, including a pivotal Phase 3 clinical trial.
Ada Torres
Ada Torres
16 Dec 2025
Island Pharmaceuticals has been granted a pivotal US patent extending protection for its antiviral drug Galidesivir as a Covid-19 treatment until 2042, reinforcing its strategic position in the antiviral market.
Ada Torres
Ada Torres
5 Dec 2025
Recce Pharmaceuticals has reported compelling preclinical results for its inhaled anti-infective RECCE 327, demonstrating potent activity against multidrug-resistant pneumonia bacteria in mice models.
Ada Torres
Ada Torres
26 Nov 2025
HeraMED has inked a 12-month commercial agreement with Philips’ U.S. subsidiary to deliver an integrated digital maternity care platform to American hospitals, combining cutting-edge monitoring devices with HeraMED’s remote patient monitoring technology.
Ada Torres
Ada Torres
25 Nov 2025
Island Pharmaceuticals has engaged a top Washington DC government affairs firm to accelerate its US biodefence strategy, focusing on its antiviral drug Galidesivir amid promising FDA regulatory signals.
Ada Torres
Ada Torres
20 Nov 2025